What is Zacks Small Cap’s Estimate for ABEO Q3 Earnings?

Abeona Therapeutics Inc (NASDAQ:ABEO) – Equities researchers at Zacks Small Cap issued their Q3 2025 EPS estimates for shares of Abeona Therapeutics in a research note issued on Monday, March 24th. Zacks Small Cap analyst D. Bautz forecasts that the biopharmaceutical company will post earnings of ($0.34) per share for the quarter. The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($1.16) per share. Zacks Small Cap also issued estimates for Abeona Therapeutics’ Q4 2025 earnings at ($0.04) EPS, FY2025 earnings at ($1.05) EPS, FY2026 earnings at ($0.20) EPS and FY2027 earnings at $0.40 EPS.

Other equities research analysts have also recently issued research reports about the company. Oppenheimer started coverage on Abeona Therapeutics in a research note on Wednesday, March 5th. They set an “outperform” rating and a $16.00 target price for the company. StockNews.com upgraded shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of Abeona Therapeutics in a research report on Monday. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $17.50.

Abeona Therapeutics Stock Up 1.0 %

Shares of NASDAQ ABEO opened at $5.04 on Thursday. The business has a 50-day moving average of $5.42 and a two-hundred day moving average of $5.81. The company has a market capitalization of $219.09 million, a price-to-earnings ratio of -1.87 and a beta of 1.79. Abeona Therapeutics has a 1 year low of $3.05 and a 1 year high of $8.45. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12.

Abeona Therapeutics (NASDAQ:ABEO) last issued its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.19.

Institutional Investors Weigh In On Abeona Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Adage Capital Partners GP L.L.C. increased its holdings in shares of Abeona Therapeutics by 20.1% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,902,360 shares of the biopharmaceutical company’s stock valued at $21,736,000 after acquiring an additional 652,366 shares during the period. Western Standard LLC increased its stake in Abeona Therapeutics by 22.8% in the fourth quarter. Western Standard LLC now owns 2,084,418 shares of the biopharmaceutical company’s stock valued at $11,610,000 after purchasing an additional 386,321 shares during the period. 683 Capital Management LLC raised its holdings in shares of Abeona Therapeutics by 17.3% in the fourth quarter. 683 Capital Management LLC now owns 791,845 shares of the biopharmaceutical company’s stock valued at $4,411,000 after buying an additional 116,845 shares during the last quarter. Citigroup Inc. boosted its stake in shares of Abeona Therapeutics by 10.1% during the third quarter. Citigroup Inc. now owns 616,668 shares of the biopharmaceutical company’s stock worth $3,897,000 after buying an additional 56,332 shares during the period. Finally, Geode Capital Management LLC grew its holdings in shares of Abeona Therapeutics by 21.7% during the third quarter. Geode Capital Management LLC now owns 465,317 shares of the biopharmaceutical company’s stock worth $2,942,000 after buying an additional 83,050 shares during the last quarter. Hedge funds and other institutional investors own 80.56% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.